WORCESTER, Mass., July 13, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first “composition of matter” patent to be issued relating to one of their development products.
